Johnson & Johnson entwickeln einen Impfstoff, bei dem in einer Studie erforscht wird, ob evtl. nur eine Impfdosis erforderlich ist. Es ist ein Adenovirus- Vektorimpfstoff.
Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype vector encoding a full-length and stabilized SARS-CoV-2 spike protein.
Five serious adverse events in the phase 1-2a trial occurred:
one case of hypotension (unrelated to the vaccine because of a history of recurrent hypotension)
one case of bilateral nephrolithiasis (participant with a history of kidney stones/ not related)
one case of legionella pneumonia (not related)
one worsening of multiple sclerosis (which had remained undiagnosed for approximately 8 to 10 years on the basis of findings on magnetic resonance imaging (not related))
one case of fever that resulted in hospitalization because of suspicion of Covid-19